Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhu-pGSN plus standard of care for severe COVID-19 pneumonia
2020-002460-31Phase 2Completed
- Sponsor
- BioAegis Therapeutics
- Start
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus pneumonia and coronavirus disease 2019 (COVID-19) comparing rhu-pGSN plus standard of care with placebo plus standard of care (2 arms). Primary endpoints: survival without organ failure on Day 14 and safety and tolerability. Started Jun 2020; status: completed.
02
Drugs
Recombinant human plasma gelsolin
03
Conditions
coronavirus pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002460-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002460-31.